Literature DB >> 19242496

Imatinib dose escalation for chronic phase-chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400 mg daily standard therapy.

D Rea, G Etienne, S Corm, P Cony-Makhoul, M Gardembas, L Legros, V Dubruille, S Hayette, F-X Mahon, J-M Cayuela, F E Nicolini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19242496     DOI： 10.1038/leu.2009.32

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  7 in total

Review 1.  Molecular resistance: an early indicator for treatment change?

Authors:  Carmen Fava; Hagop Kantarjian; Jorge Cortes
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-01-28

2.  Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.

Authors:  François Guilhot; Timothy P Hughes; Jorge Cortes; Brian J Druker; Michele Baccarani; Insa Gathmann; Michael Hayes; Camille Granvil; Yanfeng Wang
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

Review 3.  Chronic myelogenous leukemia: treatment and monitoring.

Authors:  Nikolas von Bubnoff; Justus Duyster
Journal:  Dtsch Arztebl Int       Date:  2010-02-19       Impact factor: 5.594

4.  Stochastic dynamics of leukemic cells under an intermittent targeted therapy.

Authors:  Nicola Pizzolato; Dominique Persano Adorno; Davide Valenti; Bernardo Spagnolo
Journal:  Theory Biosci       Date:  2011-04-09       Impact factor: 1.919

Review 5.  Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib.

Authors:  Brady Stein; B Douglas Smith
Journal:  Clin Ther       Date:  2010-05       Impact factor: 3.393

Review 6.  Management options for refractory chronic myeloid leukemia: considerations for the elderly.

Authors:  Massimo Breccia; Giuliana Alimena
Journal:  Drugs Aging       Date:  2013-07       Impact factor: 3.923

7.  Patan hospital experience in treating philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukemia patients with gleevec (imatinib mesylate); the first generation specific tyrosine kinase inhibitor.

Authors:  Gyan K Kayastha; Padma Gurung; Paras K Acharya; Buddhi P Paudyal; Bruce Hayes; Mark Zimmerman; Arjun Karki; Aaron S Mansfield
Journal:  BMC Blood Disord       Date:  2010-12-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.